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OBJECTIVES: During the 2009 influenza A H1N1 pandemic, it became difficult to differentiate viral infections from
other conditions in patients admitted to the intensive care unit. We sought to evaluate the behavior and diagnostic
utility of procalcitonin, C-reactive protein and four other molecules in patients with suspected 2009 Influenza A
H1N1 infection.
METHODS: The serum levels of procalcitonin, C-reactive protein, tumor necrosis factor a, interferon c, interleukin
1b, and interleukin 10 were tested on admission and on days 3, 5, and 7 in 35 patients with suspected 2009 H1N1
infection who were admitted to two ICUs.
RESULTS: Twelve patients had confirmed 2009 influenza A H1N1 infections, 6 had seasonal influenza infections, and
17 patients had negative swabs. The procalcitonin levels at inclusion and on day 3, and the C-reactive protein levels
on day 3 were higher among subjects with 2009 influenza A H1N1 infections. The baseline levels of interleukin 1b
were higher among the 2009 influenza A H1N1 patients compared with the other groups. The C-reactive protein
levels on days 3, 5, and 7 and procalcitonin on days 5 and 7 were greater in non-surviving patients.
CONCLUSION: Higher levels of procalcitonin, C-reactive protein and interleukin-1b might occur in critically ill
patients who had a 2009 H1N1 infection. Neither procalcitonin nor CRP were useful in discriminating severe 2009
H1N1 pneumonia. Higher levels of CRP and procalcitonin appeared to identify patients with worse outcomes.
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INTRODUCTION
The 2009 influenza A H1N1 (2009 H1N1) pandemic
generated a significant burden to health care services around
the world (1,2). This virus was first identified in Mexico and the
United States (March-April 2009) and quickly spread world-
wide (3,4). In Brazil, as in some other southern hemisphere
countries, the outbreak started in June, lasted approximately 18
weeks, and was responsible for at least 1,600 deaths (2,5).
The 2009 H1N1 infection caused a broad spectrum of
clinical syndromes, ranging from afebrile upper respiratory
illness to fulminating viral pneumonia and acute respiratory
distress syndrome (2,6-8). The real-time reverse transcrip-
tase polymerase chain reaction (rRTPCR) analysis per-
formed on respiratory secretions has a sensitivity of 98 to
100% and a specificity of 100% in identifying the 2009 H1N1
infection (9). However, with a turnaround time of 2-3 days,
its results do not contribute to the initial therapeutic
decisions. The use of biomarkers in patients with suspected
or confirmed bacterial infections has been investigated
primarily in the critical care setting. Procalcitonin (PCT)
has been proven to be accurate in discriminating bacterial
from viral infections (10,11). However, only a few studies
have evaluated the behavior of PCT in patients with severe
Copyright  2012 CLINICS – This is an Open Access article distributed under
the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-
commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.
No potential conflict of interest was reported.
CLINICS 2012;67(4):327-334 DOI:10.6061/clinics/2012(04)05
3272009 H1N1 pneumonia (12-15). It has been suggested that
the immune response against the 2009 H1N1 virus might
diverge from that observed against the seasonal influenza
virus (16). Interestingly, elevated levels of PCT have been
observed in patients with viral 2009 H1N1 infection even
when the patients did not have a concomitant bacterial
infection (13,14).
In this study, we sought to evaluate the behavior and the
diagnostic utility of the circulating serum levels of PCT in
patients with suspected 2009 H1N1 infection and severe
acute respiratory illness. To further evaluate the immune
response in those individuals, we investigated the levels of
C-reactive protein (CRP), tumor necrosis factor a (TNF-a),
interferon c (IFN-c), interleukin 1b (IL-1b) and interleukin
10 (IL-10) in those patients.
MATERIALS AND METHODS
Study setting and subjects
This was a prospective observational study conducted
in two mixed medical and surgical intensive care units
(ICUs) in two university hospitals in southeastern Brazil.
From August to November 2009, all the patients aged $14
years old that were admitted to one of the two participant
ICUs with suspected 2009 H1N1 infection were evaluated
for potential eligibility. The following inclusion criteria
were used: (1) severe acute respiratory illness defined as
dyspnea plus bilateral infiltrates on the x-ray; (2) suspi-
cion of 2009 H1N1 infection and lack of any other obvious
etiology to explain the respiratory symptoms; and (3) a
stay of at least 24 h in the ICU. The patients who fulfilled
the inclusion criteria were included in the study on the
first day of ICU admission. The study was approved by
the Universidade Federal de Minas Gerais’ Ethic
Committee, and written informed consent was obtained
from all the patients or the next of kin. To conduct this
study and write this report, we observed the Standard for
Reporting of Diagnostic Accuracy checklist and recom-
mendations (17).
Study procedures
A dedicated fellow (MBSP) visited the participating ICUs
daily to follow the included subjects and to identify new
eligible patients. Demographic, clinical, and laboratory data
were recorded at inclusion and then daily. The radiographic
diagnostics and microbiological examinations (i.e., cultures
of urine, blood, blind bronchoalveolar lavage, and tracheal
aspirates) were performed at the discretion of the treating
physicians. Severity and organ dysfunction at admission
were defined based on the Acute Physiology and Chronic
Health Evaluation II (APACHE II) (18) and the Sepsis-
Related Organ Failure Assessment (SOFA) scores (19). All-
cause hospital mortality, ICU length of stay and hospital
length of stay were also recorded. No diagnostic or
therapeutic intervention was performed as part of the study
protocol.
Identification of the 2009 H1N1 virus
All the included patients were submitted to the collection
of nasopharyngeal swabs or aspirates upon admission to the
ICU. These samples were tested for 2009 H1N1 in a public
reference laboratory according to the Centers for Disease
Control (CDC) rRTPCR Protocol for the Detection and
Characterization of Swine Influenza (version 2009) (20).
PCT and CRP measurement
Peripheral blood samples were collected in the morning
using vacuum tubes (BD Vacutainer SST II Plus plastic
tubes; Becton Dickinson Diagnostic Systems, Sa ˜o Paulo,
Brazil). After centrifugation, the serum was stored at -80˚C
until analyzed. The circulating plasma PCT and CRP levels
were measured at inclusion (baseline) and on days 3, 5, and
7 following inclusion until the time of patient death or ICU
discharge. The PCT levels were measured using an enzyme-
linked fluorescent immunoassay (PCT Vidas Brahms,
bioMe ´rieux, France) with an assay sensitivity of 0.05 mg/L,
which was approximately fourfold higher than the mean
normal levels. The circulating CRP levels were measured
using dry chemistry with the Ektachem 950ICR System
(Johnson & Johnson Clinical Diagnostics, Inc., Rochester,
NY, USA). The detection limit for CRP was 7 mg/dL.
Values above 10 mg/dL were considered abnormal.
Cytokine Measurements
The plasma levels of TNF-a, IFN-c, IL-10, and IL-1b were
measured using the enzyme-linked immunoassay (ELISA)
sandwich (Duoset R & D Systems, Minneapolis, MN, USA)
with pairs of marked antibodies. These cytokines were
tested at inclusion and on days 3, 5, and 7 according to the
ICU length of stay.
Statistical analysis
The categorical variables are expressed as numbers and
percentages. The continuous variables are stated as the
means ¡ SD for normally distributed variables and as
medians and interquartile ranges (IQR) for non-normally
distributed variables. The comparability among the groups
was analyzed using the x
2 tests (Yates’ test or Fisher’s exact
test), the two-sample t test, the Mann-Whitney U test or the
Kruskall-Wallis test. The ROC curves were built to establish
the accuracy of the inflammatory molecules tested in the
identification of patients infected by 2009 H1N1. The
positive and negative predictive values were calculated
once the best cutoffs for these molecules were defined. The
Spearman test was used to establish correlations between
parameters. The data collected were analyzed using the
SPSS software (SPSS 17.0; SPSS Inc., Chicago, United States).
To compare the three studied groups regarding the behavior
of the CRP and PCT levels over time, i.e., for the four
measurements (baseline, day 3, day 5, and day 7), we fitted
a linear mixed-effect model using R software (lme4 and nlme
packs). Therefore, the CRP and PCT levels were trans-
formed to normally distributed variables with square root
and natural logarithm calculations, respectively. Signifi-
cance was reported as a p-value of 0.05 or less.
RESULTS
Characteristics of the study population
Forty-nine patients were assessed for eligibility. Five
patients did not meet the inclusion criteria: two patients had
an alternate diagnosis, and three patients stayed in the ICU
for less than 24 hours. Among the 44 remaining patients,
nine were excluded from the final analysis: for eight
patients, we were unable to obtain the results for 2009
H1N1 rRTPCR from the reference laboratory probably due
to inaccurate measurements, and in one patient, the results
of the circulating levels of PCT upon admission were
unavailable.
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Influenza A H1N1
(n=12) Seasonal Influenza (n=6) Negative rRTPCR (n=17) p-value
a
Age (mean¡SD) 37.5 (21.6) 39.2 (11.8) 39.7 (22.0) 0.81
Sex (male, %) 6 (50) 1 (17) 7 (41) 0.39
Underlying medical condition (n, %) 8 (67) 3 (50) 10 (59) 0.78
Asthma 0 (0) 1 (17) 3 (18)
Chronic obstructive pulmonary disease 2 (17) 0 (0) 1 (6)
Diabetes 1 (8) 0 (0) 2 (12)
Chronic cardiovascular disease 2 (17) 1 (17) 2 (12)
Chronic renal disease 1 (8) 0 (0) 0 (0)
Immunosuppression 1 (8) 1 (17) 1 (6)
Pregnancy 2 (17) 0 (0) 3 (18)
Obesity 1 (8) 1 (17) 0 (0)
Apache 2 (median, IQR) 14.5 (11.0) 11.0 (5.0) 10.0 (8.0) 0.24
SOFA at admission (median, IQR) 6.0 (6.0) 3.0 (2.0) 2.0 (2.0) 0.006
PaO2/FiO2 at admission (median, IQR) 160 (127) 200 (119) 172 (136) 0.31
Positive cultures at admission (n, %)
b 3 (25) 0 (0) 3 (18) 0.32
Blind-BAL or tracheal aspirate 2 (17) 0 (0) 2 (12)
Blood 2 (17) 0 (0) 1 (6)
Vasopressors (n, %) 11 (91.7) 3 (50) 8 (47.1) 0.04
Hydrocortisone (n, %) 7 (58.3) 2 (33.3) 9 (52.9) 0.60
Endotracheal intubation (n,%) 11 (91.7) 3 (50) 12 (70.6) 0.14
Mechanical ventilation (median days, IQR) 10 (11) 12 (29) 4 (23) 0.91
Acute kidney injury (n, %)
c 8 (66.7) 2 (33.3) 3 (17.6) 0.03
Hemodialysis (n, %) 6 (50) 2 (33.3) 3 (17.6) 0.18
ICU LOS (median days, IQR) 12 (14) 17.5 (25) 7 (21) 0.65
Hospital LOS (median days, IQR) 16.5 (21) 28.5 (55) 18 (21) 0.85
Mortality (n, %) 5 (41.7) 0 (0) 6 (35.3) 0.18
LOS- length of stay; IQR- interquartile range; SOFA – sequential organ failure assessment
aFor comparison among the three groups, significant if , 0.05.
bOne patient with H1N1 infection had both the respiratory secretion and the blood cultures positive for Staphylococcus aureus.
cAccording to the AKIN criteria
21
Figure 1 - The circulating levels of procalcitonin observed in the studied patients at the four points of measurement, according to the
respective group.
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baseline clinical characteristics (i.e., comorbidities, SOFA
score and APACHE score) were similar between the
included and excluded patients (data not shown). The
rRTPCR analysis was performed in a median of 6 (range:0 -
16) days after the onset of symptoms. Twelve (34.3%)
patients had confirmed 2009 H1N1 infections, 6 (17.1%)
patients had seasonal influenza infections and 17 (48.6%)
patients yielded swabs that were negative for the influenza
virus. The most frequent diagnoses among individuals with
negative rRTPCR were undefined pulmonary disease with
bilateral infiltrates (5 patients), microbiologically confirmed
community-acquired pneumonia (3 patients), severe asthma
and pulmonary embolism (2 patients each). The patients’
clinical characteristics are displayed in table 1. The SOFA
score measured at inclusion was higher among 2009 H1N1-
infected individuals compared with the other groups; the
use of vasopressors and the occurrence of acute renal failure
were also higher among these patients (21).
Thirty-two (91.4%) patients had blood cultures obtained
at admission, and 16 (61.5% of those who underwent
tracheal intubation) provided respiratory samples that were
tested for bacterial agents. Positive blood culture results
were observed in two patients of the 2009 H1N1 group and
in one patient with negative rRTPCR results. Concerning the
respiratory samples, two patients in the 2009 H1N1 group
(both with S. aureus) and two patients in the negative
rRTPCR group (1 with S. aureus and 1 with K. pneumoniae)
had positive results.
Plasma levels of PCT and CRP
The circulating levels of PCT at inclusion and on day 3
were significantly higher among subjects with confirmed
H1N1 infections (median 7.22 mg/L, IQR: 95.92) compared
with the patients in the seasonal influenza group (0.28 mg/L,
IQR: 1.39) and the patients without influenza (0.85 mg/L,
IQR: 3.29); p=0.005 and p=0.015, respectively. Similar
results were observed when the circulating levels of CRP
that were tested on day 3 were compared among the three
groups: medians of 179 mg/dl (IQR: 274) in the 2009 H1N1
group, 110 mg/dl (IQR: 119) in the seasonal influenza
group, and 123 mg/dl (IQR: 106) in the patients without an
influenza infection (p=0.024). A smaller, although still
significant, difference was observed for both markers when
a subgroup analysis excluding the three patients with
bacteremia at inclusion was performed.
Regarding the changes in the levels of CRP and PCT
during the first seven days of follow-up in all the studied
patients, the levels of both markers decreased with time
(p=0.003 for PCT and p=0.079 for CRP). The trends were
independently compared among the groups for each
marker. For both markers, the patients in the 2009 H1N1
group were primarily responsible for this trend. When
the entire period of time was considered, the CRP and
PCT values were significantly lower in the seasonal
influenza (p=0.029 for CRP and p=0.009 for PCT,
respectively) and noninfluenza groups (p=0.041 for
CRP and p=0.010 for PCT, respectively) compared with
the H1N1 patients.
Figure 2 - The circulating levels of C-reactive protein observed in the studied patients at the four points of measurement, according to
the respective group.
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Except for the baseline levels of IL-1b, which were proven
to be significantly higher among the patients in the 2009
H1N1 group (p=0.014) compared with the other groups, no
other difference was observed concerning the circulating
levels of the tested cytokines. The AUC for IL-1b values
indicating H1N1 infection was 0.79 (CI, 0.62 to 0.96); at a
cutoff point set at 30 pg/ml, the sensitivity was 91%, and
the specificity was 65%. The levels of IL-1b remained
significantly higher among patients infected with 2009
H1N1 influenza when the subgroup with bacteremia was
excluded from the analysis (p=0.04).
Inflammatory molecules and outcome
We further evaluated the time course of the tested
molecules in relation to in-hospital mortality. Eleven
(31.4%) out of the 35 included patients died during
hospitalization. In the analysis that compared the CRP and
PCT levels with the outcome, the CRP levels on days 3, 5 and
7( p=0.047, 0.012 and 0.008, respectively) and the PCT levels
on days 5 and 7 (p=0.019 and 0.001, respectively) were
significantly higher in non-surviving patients. No studied
cytokine was associated with all-cause hospital mortality.
DISCUSSION
In this observational study on critically ill patients with
suspected 2009 H1N1 infection, we observed higher
circulating levels of PCT and CRP among 2009 H1N1-
infected individuals compared with patients with seasonal
influenza and non-influenza-related respiratory distress.
The IL-1b levels were also higher among 2009 H1N1
subjects compared with the two other studied groups on
admission. The increased levels of PCT and CRP throughout
the course of the disease were associated with higher
mortality.
Many studies have tested the role of PCT as a tool to
differentiate infectious and noninfectious systemic inflam-
matory response syndrome (SIRS) (22-25) and to distinguish
between bacterial and viral infections (10,11). Most of the
studies observed better results with PCT than with CRP and
other markers in discriminating these conditions. Moreover,
the PCT levels during the first days of antibiotic therapy
Figure 3 - The circulating levels of CRP during the first seven days of follow-up in the three studied groups.
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outcome (26). The higher levels of PCT presented by the
patients with 2009 H1N1 infection in the present study
challenges the notion that the levels of this marker would
remain normal or only slightly elevated among patients
with viral conditions. As suggested by the SOFA scores, the
most probable explanation of our results is the significantly
greater severity of the 2009 H1N1 subjects. Increased PCT
concentrations have already been shown to be associated
with higher severity scores (i.e., SOFA score) in critical care
patients with sepsis (27). Both the PCT and CRP levels were
useless in discriminating 2009 H1N1 infection from other
causes of respiratory distress in our study.
Although this possibility was uniformly present among
the 35 studied subjects, we cannot rule out unidentified
bacterial coinfection among the 2009 H1N1 patients as a
hypothetical reason to explain their elevated CRP and PCT
serum levels. Guervilly et al. observed that patients infected
with this virus might present high PCT levels despite the
absence of bacterial coinfection (13). Similar results were
reported by Cunha et al. in subjects with a definite or
probable 2009 H1N1 diagnosis (14).
Conversely, several authors have observed lower levels of
circulating PCT among patients with an isolated 2009 H1N1
infection compared with those with a bacterial or mixed
(bacterial and viral) infection (12,28). In a multicenter, retro-
spective study conducted in 23 French ICUs, Cuquemelle et al.
investigated the initial circulating levels of PCT presented by
52 patients admitted with confirmed 2009 H1N1 infection.
They found that the PCT levels of 0.8 mg/L combined with
alveolar pulmonary infiltrates are strongly suggestive of
bacterial coinfection (OR12.9; 95% CI 3.2–51.5) (15).
Regarding the tested cytokines, only the baseline levels of
IL-1b were higher among 2009 H1N1-infected subjects. The
IL-1b levels also maintained their association with H1N1
infection in the analysis, excluding the patients with
bacteremia. At a cutoff of 30 pg/ml, the IL-1 b levels
accurately identified the patients infected with the virus.
The levels of IL-1 b have been found to be elevated in
patients with severe 2009 H1N1 infections (29). It has been
shown that a proinflammatory response predominates in
patients with severe 2009 H1N1 infections (30). This
inflammatory state might at least partially explain the high
levels of CRP and PCT observed.
Figure 4 - The circulating levels of PCT during the first seven days of follow-up in the three studied groups.
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significantly higher among non-survivors compared with
survivors. It has been shown that the PCT trends, not the
baseline values, are associated with the outcome in intensive
care patients (22,31). Thus, the decrease in the PCT levels might
have identified individuals with better outcomes. In other
words, patients with persistently high PCT levels had higher
mortality. Elevated CRP levels have also been associated with
poor outcomes in intensive care patients (32) and in patients
with severe community-acquired pneumonia (33). We found
that the circulating CRP levels tested on days 3, 5, and 7 also
increased in the non-survivors compared with the survivors.
This study has several limitations. First, our sample size was
small, and the investigation was conducted in only two
university hospitals. Second, we were not able to obtain lower
respiratory samples from some of the patients that underwent
invasive mechanical ventilation, which could have been
responsible for a small number of negative RT-PCR results.
The nasopharyngeal samples, however, were obtained in the
acute phase ofthe disease and beforethe institution of antiviral
therapy in most cases. Additionally, the sensitivity of rRTPCR
for influenza in the nasopharyngeal swabs is between 97.8 and
100%, and the specificity is 100% (9). Third, we were unable to
obtain culture results from respiratory samples in 38.5% of the
subjects who underwent tracheal intubation. Finally, we did
not investigate Streptococcus pneumoniae or Legionella pneumo-
phila urinary antigens.
In conclusion, in this prospective observational study, we
observed higher levels of PCT, CRP and IL-1b among
critically ill 2009 H1N1-infected patients compared with
subjects with seasonal influenza infection and noninfluenza
diagnoses. Neither PCT nor CRP was useful in the
discrimination of severe 2009 H1N1 infection from other
causes of respiratory failure. The elevated levels of PCT
and CRP might have been due to the greater severity of
certain cases with a concomitant substantial inflammatory
response, although bacterial coinfection could not be
definitively ruled out. The IL-1b values had a higher
discriminative value for 2009 H1N1 infection, and they
were not correlated with positive blood or respiratory
cultures. Overall, the PCT levels on days 5 and 7 and the
CRP levels on days 3, 5, and 7 following admission were
associated with all-cause hospital mortality.
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